---
title: "QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Product information and disease description"
description: "Formulary evidence on QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Product information and disease description. Covers Product description and Place of product in therapy. 77 evidence topics quoted from 58 sources."
canonical: "https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Development status

> “The safety or efficacy has not been established for any use.”

Source: [Palvella Therapeutics pipeline update announcement (2023)](https://www.globenewswire.com/news-release/2023/02/21/2611988/0/en/palvella-therapeutics-announces-pipeline-update-on-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-for-serious-rare-genetic-skin-diseases-with-no-fda-approved-therapies.html)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; NDA submitted August 2026, accepted with Priority Review October 2026, PDUFA target action date February 2027

> “Oct. 28, 2026”
> “the FDA has accepted for filing and granted Priority Review to the Company’s New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.”

Source: [Palvella Therapeutics NDA acceptance and Priority Review announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-announces-fda-acceptance-and-priority-review-qtorintm)

> “August 31, 2026”
> “the Company has completed the rolling submission of its New Drug Application (NDA) to the FDA”

Source: [Palvella Therapeutics NDA submission completion announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-completes-rolling-submission-new-drug)

> “QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA”

Source: [Palvella Therapeutics World Congress of Pediatric Dermatology announcement (2025)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-qtorintm-rapamycin-39-anhydrous/)

<a id="topic-2.1.1-3"></a>

##### FDA submission: regulatory pathway

> “505(b)(2)”

Source: [Palvella Therapeutics NDA submission completion announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-completes-rolling-submission-new-drug)

<a id="topic-2.1.1-4"></a>

##### Anticipated approval and commercial launch

> “our first potential FDA approval in the first half of 2027”

Source: [Palvella Therapeutics full-year 2025 results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-reports-full-year-2025-financial-results/)

> “commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved”

Source: [Palvella Therapeutics second quarter 2026 results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-reports-second-quarter-2026-financial)

<a id="topic-2.1.1-5"></a>

##### Launch: Anticipated in the first half of 2027

> “Palvella is preparing for a potential standalone U.S. commercial launch of QTORIN™ rapamycin in the first half of 2027, subject to FDA approval.”

Source: [Palvella Therapeutics NDA acceptance and Priority Review announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-announces-fda-acceptance-and-priority-review-qtorintm)

> “a patient services organization established in preparation for a potential launch in the first half of 2027, if approved”

Source: [Palvella Therapeutics NDA submission completion announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-completes-rolling-submission-new-drug)

<a id="topic-2.1.1-6"></a>

##### Special FDA designations: Breakthrough Therapy designation

> “Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).”

Source: [Palvella Therapeutics Breakthrough Therapy designation announcement (2023)](https://www.globenewswire.com/news-release/2023/11/16/2781752/0/en/Palvella-Therapeutics-Announces-U-S-FDA-Breakthrough-Therapy-Designation-Granted-to-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Microcystic-Lymphatic-M.html)

<a id="topic-2.1.1-7"></a>

##### Special FDA designations: Fast Track designation

> “the FDA previously granted Fast Track Designation”

Source: [Palvella Therapeutics Breakthrough Therapy designation announcement (2023)](https://www.globenewswire.com/news-release/2023/11/16/2781752/0/en/Palvella-Therapeutics-Announces-U-S-FDA-Breakthrough-Therapy-Designation-Granted-to-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Microcystic-Lymphatic-M.html)

<a id="topic-2.1.1-8"></a>

##### Special FDA designations: FDA orphan-drug database

| Information | Source quotation |
| --- | --- |
| Date designated | “08/03/2021” |
| Orphan designation | “Treatment of Lymphatic Malformations” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=829421)

<a id="topic-2.1.1-9"></a>

##### Special designations: European Medicines Agency

> “Orphan Drug Designation has also been granted by EMA.”

Source: [Palvella Therapeutics pipeline update announcement (2023)](https://www.globenewswire.com/news-release/2023/02/21/2611988/0/en/palvella-therapeutics-announces-pipeline-update-on-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-for-serious-rare-genetic-skin-diseases-with-no-fda-approved-therapies.html)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Palvella Therapeutics

| Field | Quoted record |
| --- | --- |
| Sponsor | “Palvella Therapeutics, Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=829421)

<a id="topic-2.1.2.1-2"></a>

###### Product name

> “QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)”

Source: [Palvella Therapeutics investor relations website](https://ir.palvellatx.com/)

<a id="topic-2.1.2.1-3"></a>

###### Generic name

> “sirolimus”

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=829421)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Topical formulation and strength

> “QTORIN™ rapamycin 3.9% topical gel”

Source: [Palvella Therapeutics pipeline web page](https://palvellatx.com/pipeline/)

<a id="topic-2.1.2.2-2"></a>

###### Formulation stability

> “Enhanced chemical stability of rapamycin at room temperature for 36 months.”

Source: [PeDRA (2024)](https://www.palvellatx.com/wp-content/uploads/2024/10/Pedra-2024-Fit-For-Purpose-Martini.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Summary

The sponsor describes a potential annual pricing range of approximately $100,000 to $200,000 per patient. The cited presentation does not identify this range as an established ASP or WAC.

Source: [Palvella Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_2.htm)

<a id="topic-2.1.2.3-2"></a>

###### Product pricing information

> “Annual ~$100k-$200k pricing range per patient”
> “Supported by Phase 3 SELVA data, payor testing, analogues”

Source: [Palvella Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_2.htm)

<a id="topic-2.1.2.3-3"></a>

###### Established average sales price and wholesale acquisition cost

No evidence found.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Drug class

> “rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.”

Source: [Palvella Therapeutics website](https://www.palvellatx.com/)

<a id="topic-2.1.2.4-2"></a>

###### Product-specific AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Anticipated indication

> “microcystic lymphatic malformations (microcystic LMs)”

Source: [Palvella Therapeutics investor relations website](https://ir.palvellatx.com/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Local inhibition of mTOR signaling: formulation design

> “to deliver rapamycin directly to pathogenic skin tissue to achieve local, on-target inhibition of mTOR signaling while minimizing systemic exposure.”

Source: [Palvella Therapeutics first NDA module submission announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-submits-first-module-rolling-new-drug)

<a id="topic-2.1.2.6.1-2"></a>

###### Targeted delivery

> “QTORIN provides targeted rapamycin delivery to the main area of concern, usually within the deep layers of the epidermis or dermis.”

Source: [Palvella Therapeutics pipeline web page](https://palvellatx.com/pipeline/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical evidence

> “QTORIN Rapamycin Inhibits Both mTORC1 and mTORC2”
> “(N=8 Mice)”

Source: [PeDRA (2024)](https://www.palvellatx.com/wp-content/uploads/2024/10/Pedra-2024-Fit-For-Purpose-Martini.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### SELVA: rapamycin pharmacokinetics

> “below 2 ng/mL in systemic circulation for all participants at all timepoints”

Source: [Palvella Therapeutics Form 10-Q (2026)](https://ir.palvellatx.com/static-files/9b01caef-bc81-4ce3-9481-0e07b6fec802)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### SELVA: pregnancy-related exclusion criterion

> “Participants who are pregnant or planning to become pregnant”

Source: [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480)

<a id="topic-2.1.2.8-2"></a>

###### Renal impairment

No evidence found.

<a id="topic-2.1.2.8-3"></a>

###### Hepatic impairment

No evidence found.

<a id="topic-2.1.2.8-4"></a>

###### Lactation

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on QTORIN rapamycin 3.9 percent gel

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of QTORIN rapamycin 3.9 percent gel on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dosing and administration: phase 3

> “once-daily QTORIN™ rapamycin”

Source: [Palvella Therapeutics corporate update and 2026 outlook announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-provides-corporate-update-and-2026-outlook/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Dosing and administration: phase 2

> “Participants self-administered topical QTORIN rapamycin once daily for 12 weeks.”

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access

> “Palvella will consider requests from licensed treating physicians for access to investigational products in development for patient treatment purposes on a case-by-case basis.”

Source: [Palvella Therapeutics expanded access policy](https://www.palvellatx.com/expanded-access-policy)

<a id="topic-2.1.2.11-2"></a>

###### Patient-access infrastructure

> “The Company continues to build these organizations through the addition of field commercial leaders, medical science liaisons, and patient access liaisons.”

Source: [Palvella Therapeutics first NDA module submission announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-submits-first-module-rolling-new-drug)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of QTORIN rapamycin 3.9 percent gel on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Developmental lymphatic-vessel defects

> “Lymphatic malformations (LMs) are developmental defects of lymphatic vessels.”

Source: [Ghaffarpour et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36223836/)

Additional sources: [Goldenberg et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12237419/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Microcystic lymphatic malformations

<a id="topic-2.2.1.2.1-1"></a>

###### Incidence: lymphatic malformations overall

> “affecting 1 in 4000 live births”

Source: [Zenner et al. (2019)](https://insight.jci.org/articles/view/129884)

<a id="topic-2.2.1.2.1-2"></a>

###### Microcystic-specific incidence

No evidence found.

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Microcystic lymphatic malformations

<a id="topic-2.2.1.2.2-1"></a>

###### Epidemiology: microcystic lymphatic malformations

> “an estimated more than 30,000 diagnosed patients in the U.S.”

Source: [Palvella Therapeutics full-year 2025 results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-reports-full-year-2025-financial-results/)

<a id="topic-2.2.1.2.2-2"></a>

###### Epidemiology: lymphatic malformations with a cutaneous component

> “lymphatic malformations with a cutaneous component (LMC)”
> “79,920 (CI 66,600–93,250)”
> “managed prevalence of 24.1 LMC patients per 100,000 population (CI 19.6/100,000–28.4/100,000).”

Source: [Gallagher et al. (2022)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02336-3)

<a id="topic-2.2.1.2.2-3"></a>

###### Annual managed prevalence: distinction from total national prevalence

> “It was not designed to estimate the total national prevalence of LMC”

Source: [Gallagher et al. (2022)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02336-3)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Natural history

> “microcystic LMs are persistent and progressive and do not spontaneously regress.”

Source: [Palvella Therapeutics rolling review announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/fda-grants-rolling-review-palvellas-qtorintm-rapamycin-nda)

<a id="topic-2.2.1.3-2"></a>

###### Spontaneous regression: head and neck lymphatic malformations

> “macrocystic composition emerged as the strongest possible predictor”

Source: [Bonilla-Velez et al. (2025)](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2831727)

<a id="topic-2.2.1.3-3"></a>

###### Lymphatic malformations: complications affecting vital functions

> “may cause serious complications that threaten vital functions such as compression of the airways.”

Source: [Ghaffarpour et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36223836/)

<a id="topic-2.2.1.3-4"></a>

###### Microcystic-specific survival and mortality estimates

No evidence found.

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology and genetics

> “Lymphatic malformations (LMs) are congenital, nonneoplastic vascular malformations associated with postzygotic activating PIK3CA mutations.”

Source: [Zenner et al. (2019)](https://insight.jci.org/articles/view/129884)

<a id="topic-2.2.1.4-2"></a>

###### Genetics, mechanisms, and therapeutic strategies

> “caused mostly by somatic mutations”

Source: [Mäkinen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34166072/)

Additional sources: [Kamireddy et al. (2026)](https://www.ovid.com/jnls/jova/fulltext/10.1097/jova.0000000000000133~microcystic-and-macrocystic-lymphatic-malformations-distinct); [Canaud et al. (2021)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01929-8)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Initial imaging assessment

> “Ultrasonography is the imaging modality for the initial assessment of LMs”

Source: [Leboulanger et al. (2023)](https://link.springer.com/article/10.1186/s13023-022-02608-y)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Cutaneous symptoms: lymphorrhea, bleeding, pain, itching, and malodor

> “lymphorrhea, bleeding, pain, itching, malodor, and functional deficits.”

Source: [Gallagher et al. (2022)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02336-3)

<a id="topic-2.2.1.6-2"></a>

###### Infectious and inflammatory symptoms: pain and chronic oozing wounds

> “LMs are also highly immunologically reactive, and are prone to recurrent infections and inflammation causing pain as well as chronic oozing wounds.”

Source: [Ghaffarpour et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36223836/)

<a id="topic-2.2.1.6-3"></a>

###### Oral and airway symptoms: tongue involvement

> “hemorrhage, excessive salivation, speech disturbances, difficulties chewing and swallowing, airway obstruction, and orthodontic abnormalities”

Source: [Wiegand et al. (2009)](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/410557)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Skeletal and dental complications: tongue involvement

> “mandibular prognathism and malocclusion.”

Source: [Wiegand et al. (2009)](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/410557)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Microcystic lymphatic malformations

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Humanistic burden: tongue involvement

> “Functional impairment and cosmetic deformity significantly affect the quality of life of patients with lymphatic malformations of the tongue.”

Source: [Wiegand et al. (2009)](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/410557)

<a id="topic-2.2.1.8.1-2"></a>

###### Long-term health-related quality of life: comparison with population norms

> “Overall HRQoL paralleled age-appropriate norms in the general population, but some subgroups had lower levels.”

Source: [Ghaffarpour et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30556934/)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient-reported outcomes: Lymphatic Malformation Function instrument

> “a preliminary parent-report assessment designed to measure outcomes in children with cervicofacial lymphatic malformation”

Source: [Kirkham et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5938064/)

<a id="topic-2.2.1.8.1-4"></a>

###### Patient-reported outcomes: functional and symptom impacts in pediatric head and neck lymphatic malformations

> “Both adolescent patients and parents of younger children reported significant symptom and functional effects of this disease.”
> “Adolescents reported frequent sickness as the domain with greatest impact. Sleep was more affected in adolescents with higher stage lesions. Parents of younger children reported greatest impact on breastfeeding.”
> “For adolescents, lesion stage predicted perceived social stigma (controlling for age), whereas increasing age was associated with greater impact from swelling (controlling for stage).”

Source: [Balakrishnan et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22675002/)

<a id="topic-2.2.1.8.1-5"></a>

###### Gap between existing burden measures and reported impacts

> “Current disease burden measures, treatment decision pathways, and outcome measures do not consider such effects, although these problems lead patients and parents to seek medical care.”

Source: [Balakrishnan et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22675002/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Pediatric lymphatic malformations: United States inpatient burden, study years

> “years 2000, 2003, 2006, and 2009”

Source: [Cheng et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5647489/)

<a id="topic-2.2.1.8.2-2"></a>

###### Pediatric lymphatic malformations: United States inpatient burden, hospital charges

> “Average total charges per admission were $30,995”

Source: [Cheng et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5647489/)

Additional sources: [Kitchloo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39213789/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Microcystic lymphatic malformations on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver employment: interruption of professional activity

> “suspension of the professional activity of a parent to take care of the child”

Source: [Leboulanger et al. (2023)](https://link.springer.com/article/10.1186/s13023-022-02608-y)

<a id="topic-2.2.1.8.3-2"></a>

###### Quantified family out-of-pocket costs and productivity losses

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

No evidence found.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Conservative and Supportive Care

<a id="topic-2.2.2.1.1-1"></a>

###### Multidisciplinary treatment decisions

> “decisions must be made in multidisciplinary consultation.”

Source: [Leboulanger et al. (2023)](https://link.springer.com/article/10.1186/s13023-022-02608-y)

Additional sources: [Huerta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38914511/); [Kalwani and Rockson (2021)](https://pubmed.ncbi.nlm.nih.gov/33540133/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Sclerotherapy

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline-listed treatment for skin and mucosal lymphatic malformations

> “sclerotherapy”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Surgical Resection

<a id="topic-2.2.2.1.3-1"></a>

###### Guideline-listed treatment for skin and mucosal lymphatic malformations

> “surgical resection”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Electrocoagulation

<a id="topic-2.2.2.1.4-1"></a>

###### Guideline-listed treatment for skin and mucosal lymphatic malformations

> “electrocoagulation”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Laser Therapy

<a id="topic-2.2.2.1.5-1"></a>

###### Guideline-listed treatment for skin and mucosal lymphatic malformations

> “laser”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Radiofrequency Ablation

<a id="topic-2.2.2.1.6-1"></a>

###### Guideline-listed treatment for skin and mucosal lymphatic malformations

> “radiofrequency ablation”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Topical mTOR Inhibitors

<a id="topic-2.2.2.1.7-1"></a>

###### French national diagnosis and care protocol: topical sirolimus

> “Topical sirolimus is under clinical evaluation for these superficial cutaneous and mucosal LMs (NCT03972592, NCT04128722).”

Source: [Leboulanger et al. (2023)](https://link.springer.com/article/10.1186/s13023-022-02608-y)

<a id="topic-2.2.2.1.7-2"></a>

###### Medical therapies for pediatric lymphatic malformations: systematic review

> “ultimately included 77 studies.”
> “Reported success rates were variable”
> “sirolimus (topical) (n = 13/15)”

Source: [Hollman et al. (2026)](https://journals.sagepub.com/doi/10.1177/12034754251386785)

<a id="topic-2.2.2.1.7-3"></a>

###### Other topical sirolimus formulations: 0.2% gel in pediatric superficial microcystic lymphatic malformations, case series

> “0.2% topical sirolimus gel twice daily”

Source: [Cui et al. (2026)](https://www.dovepress.com/topical-sirolimus-gel-for-the-treatment-of-superficial-microcystic-lym-peer-reviewed-fulltext-article-CCID)

<a id="topic-2.2.2.1.7-4"></a>

###### Other topical sirolimus formulations: upper limb superficial lymphatic malformation case report

> “a noticeable reduction in lesion size and bleeding was observed”

Source: [Abtahi-Naeini et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12742332/)

<a id="topic-2.2.2.1.7-5"></a>

###### Other topical sirolimus formulations: 1% rapamycin ointment case report

> “1% rapamycin ointment”

Source: [García-Montero et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28557723/)

<a id="topic-2.2.2.1.7-6"></a>

###### Other topical sirolimus formulations: microcystic lymphatic malformation case report with local irritation

> “a local irritation occurred and the dose was decreased to once daily.”

Source: [Çalışkan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30133999/)

<a id="topic-2.2.2.1.7-7"></a>

###### Other topical sirolimus formulations: efficacy and absorption in children with vascular anomalies

> “topical sirolimus 0.1%”

Source: [Le Sage et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29790593/)

Additional sources: [Lapa and Sandre (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13076952/); [García-Montero et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30296533/); [Badia et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31930696/); [Dodds et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31957126/); [Ivars and Redondo (2017)](https://pubmed.ncbi.nlm.nih.gov/27784048/); [Yonekura et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36044195/); [Vandersteen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39984430/); [Gu and Sebaratnam (2024)](https://pubmed.ncbi.nlm.nih.gov/37717734/); [Cai et al. (2023)](https://www.jaad.org/article/S0190-9622%2819%2930165-3/fulltext)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Compression Therapy and Lymphatic Drainage

Additional sources: [Leboulanger et al. (2023)](https://link.springer.com/article/10.1186/s13023-022-02608-y)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Systemic mTOR Inhibitors

<a id="topic-2.2.2.1.9-1"></a>

###### Sirolimus systematic review

> “Clinically meaningful, long-term improvement (up to 3 years) was noted in 92% (46/50), mostly previously treated subjects.”
> “prospective, controlled trials are clearly needed”

Source: [Teng et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35852876/)

<a id="topic-2.2.2.1.9-2"></a>

###### Sirolimus for pediatric head and neck lymphatic malformations: systematic review

> “97 paediatric patients”
> “94 mild-to-moderate adverse events were reported.”

Source: [Saibene et al. (2023)](https://link.springer.com/article/10.1007/s00405-023-07991-1)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 PI3K Inhibitors

Additional sources: [Leboulanger et al. (2023)](https://link.springer.com/article/10.1186/s13023-022-02608-y)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Kampo Herbal Formulas

<a id="topic-2.2.2.1.11-1"></a>

###### Japanese guideline: geographically limited use

> “Kampo formulas”
> “nearly exclusively in Japan”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="heading-2.2.2.1.12"></a>

###### 2.2.2.1.12 Limitations of Current Therapies

<a id="topic-2.2.2.1.12-1"></a>

###### Summary

Available procedural treatments can be limited by complications, recurrence, and repeated procedures. The Japanese guideline recommendation addressing skin and mucosal lymphatic malformations has a strength rating of 2, described as weak, and an evidence rating of D, described as very weak.

A systematic review of sirolimus reported improvement in 46 of 50 evaluable individuals (92%), mostly previously treated, while identifying the need for prospective controlled trials. These heterogeneous supporting data do not establish the comparative effectiveness of QTORIN rapamycin against individual procedures, compounded topical formulations, or systemic therapy.

Source: [Palvella Therapeutics rolling review announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/fda-grants-rolling-review-palvellas-qtorintm-rapamycin-nda); [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0); [Teng et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35852876/)

<a id="topic-2.2.2.1.12-2"></a>

###### Current treatment limitations

> “Surgery, sclerotherapy and laser can be limited by recurrence and repeated procedures”

Source: [Palvella Therapeutics rolling review announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/fda-grants-rolling-review-palvellas-qtorintm-rapamycin-nda)

<a id="topic-2.2.2.1.12-3"></a>

###### Japanese clinical practice guidelines: CQ37 strength of recommendation

> “2 (weak)”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="topic-2.2.2.1.12-4"></a>

###### Japanese clinical practice guidelines: CQ37 evidence

> “D (very weak)”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="topic-2.2.2.1.12-5"></a>

###### Japanese clinical practice guidelines: complications and recurrence

> “Each of these treatments is effective but may cause complications and recurrence”

Source: [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

QTORIN rapamycin has been studied as a self-administered topical treatment. SELVA required clinically confirmed superficial/cutaneous microcystic lymphatic malformations and excluded complicated vascular anomalies with severe systemic symptoms requiring systemic therapy. The sponsor describes the diagnosed population as concentrated in vascular anomaly centers. The report does not establish an approved treatment sequence or an approved prescribing setting for this investigational formulation.

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101); [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480); [Palvella Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_2.htm); [Palvella Therapeutics NDA submission completion announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-completes-rolling-submission-new-drug)

<a id="topic-2.2.2.2-2"></a>

###### Care setting

> “with concentration in vascular anomaly centers”

Source: [Palvella Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_2.htm)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### SELVA: pediatric subgroup

| Information | Source quotation |
| --- | --- |
| Subgroup | “aged 6–11 years (n=13)” |
| Mean response | “(mLM-IGA) of +2.46 at Week 24 (p<0.001).” |
| Response proportion | “100% of participants in this cohort” |

Source: [Palvella Therapeutics SELVA and TOIVA data announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-presents-new-selva-and-toiva-data-2026/)

<a id="topic-2.2.2.3-2"></a>

###### SELVA: pediatric subgroup response categories

> ““Much Improved” (+2) or “Very Much Improved” (+3)”

Source: [Palvella Therapeutics SELVA and TOIVA data announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-presents-new-selva-and-toiva-data-2026/)

<a id="topic-2.2.2.3-3"></a>

###### Formal treatment-by-subgroup interaction analyses

No evidence found.

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Patient and caregiver education: disease-awareness campaign

> “disease awareness campaign and BEYONDmLM.com to educate and engage patients, caregivers, and healthcare professionals on microcystic lymphatic malformations.”

Source: [Palvella Therapeutics first quarter 2026 results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-reports-first-quarter-2026-financial/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### SELVA: observed mLM-IGA improvement among efficacy-period completers aged at least 6 years

> “95% (41/43) demonstrated at least a 1-point improvement”

Source: [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/)

## Related pages
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Terms and abbreviations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations.md)
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical evidence](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Economic information and modeling report](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: References](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: prevalence by geography](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses.md)
